ArticleTransplant international : official journal of the European Society for Organ Transplantation2022
Cytomegalovirus Management in Solid Organ Transplant Recipients: A Pre-COVID-19 Survey From the Working Group of the European Society for Organ Transplantation.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Cytomegalovirus infection contributes to acute rejection in solid organ transplant recipients: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Short and Long-Term Outcomes in Kidney Transplant Recipients with Neutropenia or Leukopenia Following CMV Prophylaxis.Journal of health economics and outcomes research · 2026Article
- An international multi-site study to evaluate the analytical and clinical performance of the quantitative high-throughput Alinity m CMV assay.Microbiology spectrum · 2025Article
- Tacrolimus Pharmacotherapy: Infectious Complications and Toxicity in Organ Transplant Recipients; An Updated Review.Current drug research reviews · 2025Review
- Managing Cytomegalovirus Infection in Lung Transplant Recipients in Real Life: Results of a French Multicenter Survey.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada.Frontiers in immunology · 2025Article
- Healthcare Resource Utilization Associated with Leukopenia and Neutropenia in Kidney Transplant Recipients Receiving Valganciclovir in the United States.Journal of health economics and outcomes research · 2025Article
- Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Clinical and Economic Burden Associated With Anti-Cytomegalovirus (CMV) Prophylaxis Therapies in Adult Kidney Transplant Recipients (LECOCYT): An Observational Study.Transplant international : official journal of the European Society for Organ Transplantation · 2025Observational
- Management of cytomegalovirus infection after liver transplantation.World journal of transplantation · 2024Review
- Review
- A practical guide to real-world implementation of pre-emptive therapy for Cytomegalovirus disease prevention in high-risk seronegative liver transplant recipients with seropositive donors.Transplant infectious disease : an official journal of the Transplantation Society · 2024Article
- Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighting the Role of Advanced Practice Providers (Nurse Practitioners and Physician Assistants).Annals of transplantation · 2024Review
- Diagnosis of Human Cytomegalovirus Drug Resistance Mutations in Solid Organ Transplant Recipients-A Review.Diagnostics (Basel, Switzerland) · 2024Review
- Innate and adaptive effector immune drivers of cytomegalovirus disease in lung transplantation: a double-edged sword.Frontiers in transplantation · 2024Review
- Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients.Viruses · 2023Review
- New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease.Infectious diseases and therapy · 2023Review
- New Treatment Options for Refractory/Resistant CMV Infection.Transplant international : official journal of the European Society for Organ Transplantation · 2023Review
- National survey of prevention and management of CMV infection in pediatric kidney transplantation in comparison to clinical practice guidelines.Frontiers in pediatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections are leading causes of morbidity/mortality following solid organ transplantation (SOT) and cytomegalovirus (CMV) is among the most frequent pathogens, causing a considerable threat to SOT recipients. A survey was conducted 19 July-31 October 2019 to capture clinical practices about CMV in SOT recipients (e.g., how practices aligned with guidelines, how adequately treatments met patients' needs, and respondents' expectations for future developments). Transplant professionals completed a ∼30-minute online questionnaire: 224 responses were included, representing 160 hospitals and 197 SOT programs (41 countries; 167[83%] European programs). Findings revealed a heterogenous approach to CMV diagnosis and management and, sometimes, significant divergence from international guidelines. Valganciclovir prophylaxis (of variable duration) was administered by 201/224 (90%) respondents in D+/R- SOT and by 40% in R+ cases, with pre-emptive strategies generally reserved for R+ cases: DNA thresholds to initiate treatment ranged across 10-10,000 copies/ml. Ganciclovir-resistant CMV strains were still perceived as major challenges, and tailored treatment was one of the most important unmet needs for CMV management. These findings may help to design studies to evaluate safety and efficacy of new strategies to prevent CMV disease in SOT recipients, and target specific educational activities to harmonize CMV management in this challenging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.